| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.22 | 0.003 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |